Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy

Purpose: Although most patients with estrogen receptor (ER)–positive breast cancer benefit from endocrine therapies, a significant proportion do not. Our aim was to identify inherited genetic variations that might predict survival among patients receiving adjuvant endocrine therapies. Experimental Design: We performed a meta-analysis of two genome-wide studies; Helsinki Breast Cancer Study, 805 patients, with 240 receiving endocrine therapy and Prospective study of Outcomes in Sporadic versus Hereditary breast cancer, 536 patients, with 155 endocrine therapy patients, evaluating 486,478 single-nucleotide polymorphisms (SNP). The top four associations from the endocrine treatment subgroup were further investigated in two independent datasets totaling 5,011 patients, with 3,485 receiving endocrine therapy. Results: A meta-analysis identified a common SNP rs8113308, mapped to 19q13.41, associating with reduced survival among endocrine-treated patients [hazard ratio (HR), 1.69; 95% confidence interval (CI), 1.37–2.07; P = 6.34 × 10−7] and improved survival among ER-negative patients, with a similar trend in ER-positive cases not receiving endocrine therapy. In a multivariate analysis adjusted for conventional prognostic factors, we found a significant interaction between the rs8113308 and endocrine treatment, indicating a predictive, treatment-specific effect of the SNP rs8113308 on breast cancer survival, with the per-allele HR for interaction 2.16 (95% CI, 1.30–3.60; Pinteraction = 0.003) and HR = 7.77 (95% CI, 0.93–64.71) for the homozygous genotype carriers. A biologic rationale is suggested by in silico functional analyses. Conclusions: Our findings suggest carrying the rs8113308 rare allele may identify patients who will not benefit from adjuvant endocrine treatment. Clin Cancer Res; 21(18); 4086–96. ©2015 AACR.

[1]  F. Couch,et al.  A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis , 2014, PloS one.

[2]  H. Brauch,et al.  Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer , 2014, The Pharmacogenomics Journal.

[3]  M. Beckmann,et al.  CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations , 2013, Clinical pharmacology and therapeutics.

[4]  M. Peters,et al.  Systematic identification of trans eQTLs as putative drivers of known disease associations , 2013, Nature Genetics.

[5]  Pedro G. Ferreira,et al.  Transcriptome and genome sequencing uncovers functional variation in humans , 2013, Nature.

[6]  Martin Clynes,et al.  BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome , 2013, Breast Cancer Research.

[7]  B. Hoffman,et al.  Gadd45a levels in human breast cancer are hormone receptor dependent , 2013, Journal of Translational Medicine.

[8]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[9]  F. Couch,et al.  Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. , 2013, Cancer research.

[10]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[11]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[12]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[13]  Naiqing Zhao,et al.  Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Wei Zheng,et al.  Novel genetic markers of breast cancer survival identified by a genome-wide association study. , 2012, Cancer research.

[15]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[16]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[17]  Andrey A. Shabalin,et al.  Matrix eQTL: ultra fast eQTL analysis via large matrix operations , 2011, Bioinform..

[18]  Anbupalam Thalamuthu,et al.  A combined analysis of genome-wide association studies in breast cancer , 2011, Breast Cancer Research and Treatment.

[19]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[20]  Simak Ali,et al.  Antiestrogens and their therapeutic applications in breast cancer and other diseases. , 2011, Annual review of medicine.

[21]  M. Beckmann,et al.  Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. , 2010, Journal of the National Cancer Institute.

[22]  Peter Kraft,et al.  A Genome-Wide Association Study of Prognosis in Breast Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[23]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Carlos Caldas,et al.  Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer , 2009, International journal of cancer.

[26]  Matthew E. Ritchie,et al.  A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data , 2009, Nucleic acids research.

[27]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[28]  L. Carey,et al.  CYP2D6 and tamoxifen: DNA matters in breast cancer , 2009, Nature Reviews Cancer.

[29]  D. Easton,et al.  Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival , 2009, Clinical Cancer Research.

[30]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[31]  D. Altman,et al.  Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol , 2007, BMC Cancer.

[32]  Chien‐An Sun,et al.  Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1 , 2007, Breast Cancer Research and Treatment.

[33]  S. Wingren,et al.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.

[34]  A. Giordano,et al.  Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. , 2005, Endocrine-related cancer.

[35]  Päivi Heikkilä,et al.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients , 2005, International journal of cancer.

[36]  Jose M. Silva,et al.  Altered expression of the ZBRK1 gene in human breast carcinomas , 2004, The Journal of pathology.

[37]  Wen-Hwa Lee,et al.  Degradation of Transcription Repressor ZBRK1 through the Ubiquitin-Proteasome Pathway Relieves Repression of Gadd45a upon DNA Damage , 2003, Molecular and Cellular Biology.

[38]  P. L. Chen,et al.  Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. , 2000, Molecular cell.

[39]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[40]  H. Nevanlinna,et al.  Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? , 2000, European journal of cancer.

[41]  I. Bae,et al.  Gadd45 family proteins are coactivators of nuclear hormone receptors. , 2000, Biochemical and biophysical research communications.

[42]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Fornace,et al.  Gadd45 in stress signaling, cell cycle control, and apoptosis. , 2013, Advances in experimental medicine and biology.

[44]  L. Teh,et al.  Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. , 2012, Drug metabolism and pharmacokinetics.

[45]  Per,et al.  Mechanisms of endocrine resistance in breast cancer , 2012 .

[46]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[47]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[48]  J. Thigpen.  Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen , 2010 .

[49]  Robert Clarke,et al.  Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. , 2005, Vitamins and hormones.

[50]  Yurii S. Aulchenko,et al.  BIOINFORMATICS APPLICATIONS NOTE doi:10.1093/bioinformatics/btm108 Genetics and population analysis GenABEL: an R library for genome-wide association analysis , 2022 .

[51]  Yusuke Nakamura,et al.  A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese , 2022 .